UPPSALA, SWEDEN – December 30, 2014. Oasmia Pharmaceutical AB (publ) announced today that it has received a new MSEK 20 bank loan. The loan replaces a previous MSEK 40 bank loan which is due on December 30, 2014.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, compared to current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. Product development is based on in-house research within nanotechnology and proprietary patents. Oasmia Pharmaceutical AB’s shares, ISIN SE0000722365, are listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX).
